News ReleasesProtox files foundation patent for PORxin™ technology Monday, December 12, 2005 - Vancouver, British Columbia - Protox Therapeutics
Inc. announced today that it has filed a provisional patent application with
the United States Patent and Trademark Office entitled “Modified Pore-Forming
Toxins and Use Thereof”. This is a foundational patent application, intended
to encompass and protect several aspects of the Company’s entire PORxin™
technology. Under this application the Company’s ability to develop individual
protoxin candidates to act as either “broad spectrum” anti-cancer
agents or to treat specific cancer types would be protected. “This advance is part of our strategy to build a broad intellectual
property portfolio around our core PORxin™ technology platform,"
said Dr. Fahar Merchant, President & CEO of the Company. “It can
significantly expand our ability to design and protect novel PORxin™
candidates, allowing us to develop or partner the PORxin™ pipeline for
indications beyond those currently being pursued by Protox.” The Company’s ability to modify pore-forming toxins so that general or specific cleavage agents can activate them is included in the application’s claims, together with other modifications that allow selective targeting of pore forming toxins to specific cells. The Company anticipates that one or more of these modified pore forming toxins may be useful in the treatment of specific forms of cancer and other diseases. About Protox Therapeutics Protox Therapeutics Inc. is developing novel targeted cancer therapeutics based on engineered protein toxins. Its lead programme (PORxin™) is based on pore forming protoxins such as modified proaerolysin. PORxins™ are inactive pro-drugs that are preferentially activated at the tumour site into potent toxins by cancer specific proteases, thereby causing cancer cell death. The Company works in partnership with research groups at the University of Victoria, Johns Hopkins University, Scott & White Hospital and other research institutions. The Company’s lead candidate, PORxin™302 is being developed for the treatment of localized prostate cancer. The Company anticipates that it will be ready to file an Investigational New Drug application (IND) with the Food and Drug Administration of the United States of America (FDA) in Q4 2005 for approval to initiate a Phase I safety study with PORxin™302. For more information, contact: |
2006 Protox Therapeutics Inc. All Rights Reserved. Legal Disclaimer. |